Pharma Companies Need Better Incentives, Innovation To Invest In Neglected Diseases Pharma firms pressed to tackle neglected diseases in developing world
“Poverty-related and neglected diseases (PRNDs) disproportionately affect the world’s poorest populations. Better incentives are needed for pharmaceutical companies to develop drugs, health campaigners say. Europe plays a critical role in developing new PRND products that are saving millions of lives and millions of euros in the world’s poorest countries…” (Jacobsen, 3/11).